|

68Ga-PSMA-11 Clinical Trials

5 actively recruiting trials across 1 location

No change since May 2026

Also known as: 68Ga-PSMA-11 injection, Gallium Ga 68 Gozetotide, Illuccix, Illucix, gallium Ga 68 Gozetotide

Pipeline

Phase 2: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

  • Telix Pharmaceuticals (Innovations) Pty Limited2
  • Peking Union Medical College Hospital1
  • Novartis Pharmaceuticals1
  • First Affiliated Hospital of Fujian Medical University1

Indications

  • Cancer5
  • Prostate Cancer3
  • BCR Prostate Carcinoma1
  • Biochemical Recurrence of Malignant Neoplasm of Prostate1
  • Carcinoma of the Prostate1

Other4 trials

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
N/A
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Phase 3
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
Phase 2/3
PSMA PET Combined With MRI for the Detection of PCa
Phase 3

New York, New York1 trial

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Mount Sinai Hosp Med School

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.